Alliance / A021806
Trial Overview
Official Title
Testing The Use Of The Usual Chemotherapy Before And After Surgery For Removable Pancreatic Cancer
Study Purpose
To determine if receiving chemotherapy before and after surgery will increase the chance of pancreatic cancer staying away.
Diagnosis
Patients have removable pancreatic cancer.Eligibility
Patient must be candidate for curative intent pancreatectomy to be confirmed by central radiologic review
No prior treatment
Measurable disease
Adeno or adenosquamous cell type
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Intervention
This study has a screening step to determine if the cancer is removable by surgery. If removable, patients will continue with the study.
- Group 1: Patients will receive FOLFIRINOX, the usual four-drug regiment used to treat this type of cancer, for 8 cycles, then have surgery to remove the pancreatic cancer, then the patient will get FOLFIRINOX for 4 more cycles.
- Group 2: Patients will receive FOLFIRINOX, the usual four-drug regiment used to treat this type of cancer. Patients will have surgery to remove the pancreatic cancer, and then will get FOLFIRINOX for 12 cycles.
For more information, click the link below:
https://clinicaltrials.gov/study/NCT04340141?term=A021806&rank=1